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Sera obtained from adult volunteers inoculated with genogroup II Norwalk-like viruses (NLVs), Hawaii
virus, and Snow Mountain virus and from patients involved in outbreaks of gastroenteritis were tested for
genogroup II NLV Mexico virus-specific immunoglobulin M (IgM) by use of a monoclonal antibody, recom-
binant Mexico virus antigen (rMXV)-based IgM capture enzyme-linked immunosorbent assay (ELISA). Sera
from genogroup I Norwalk virus (NV)-inoculated volunteers and from patients involved in a genogroup I NLV
outbreak were also tested. In sera from those infected with genogroup I NV or NLVs in volunteer and outbreak
studies, only 3 of 25 were rMXV IgM positive; in contrast, 24 of 25 were IgM positive for recombinant NV
(rNV). In sera from those infected with genogroup II NLVs in volunteer and outbreak studies, 28 of 47 were
rMXV IgM positive and none were IgM positive for rNV, showing the specificity of each IgM test for its
respective genogroup. In an outbreak of gastroenteritis not characterized as being of viral etiology but
suspected to be due to NV, 7 of 13 persons had IgM responses to rMXV, whereas none had IgM responses to
rNV, thus establishing the diagnosis as genogroup II NLV infection. The rMXV-based IgM capture ELISA
developed is specific for the diagnosis of genogroup II NLV infections.
In a recent classification, the family Caliciviridae comprises
four genera: Vesivirus, Lagovirus, Norwalk-like viruses (NLVs),
and Sapporo-like viruses (14). In previous reports, viruses in
the NLV genus have been categorized in two genogroups.
Genogroup I includes the prototype Norwalk virus (NV) and
related viruses, and genogroup II includes viruses such as Snow
Mountain virus (SMV), Hawaii virus (HV), and Mexico virus
(MXV) (23, 24, 26, 31, 36). NV has been the most extensively
studied, although it currently does not seem responsible for
most gastroenteritis caused by NLVs (4, 23, 26, 34, 37). The
development of recombinant NV (rNV) has provided a highly
purified antigen for detecting immunoglobulin G (IgG) anti-
bodies against NV and genogroup I NLVs (11, 12, 15, 21, 22,
32, 33). More recently, recombinant capsid antigen has been
developed from MXV, a genogroup II NLV (24, 25). This
recombinant MXV (rMXV) antigen has been used in several
studies to detect IgG antibodies against genogroup II NLVs (7,
17, 25, 33, 34).
Testing for seroconversion with either of these recombinant
antigens requires an early acute-phase serum sample and a
convalescent-phase serum sample to detect a minimum four-
fold rise in IgG antibody levels required to diagnose infection.
We recently described a monoclonal antibody, recombinant
antigen-based IgM capture enzyme-linked immunosorbent as-
say (ELISA) for the detection of specific IgM antibodies to NV
(1). We found that IgM antibodies to NV developed by 8 days
after exposure and were not detectable in normal sera even if
high titers of IgG antibodies were present. NV-specific IgM
antibodies were not detected in sera from SMV- or HV-inoc-
ulated volunteers (1). Two studies have used immune electron
microscopy to detect IgM to genogroup II NLVs (3, 30), and
IgM responses to rMXV antigen in sera from persons infected
with small round structured viruses have been reported (17).
The purpose of this study was to determine the efficacy of a
monoclonal antibody, rMXV-based IgM capture ELISA for
the diagnosis of genogroup II NLV infections.
MATERIALS AND METHODS
Serum samples. Sera were obtained from patients in volunteer studies and in
outbreaks of gastroenteritis. For sera from individuals known to be infected with
genogroup I NLVs, nine paired sera were from NV-inoculated volunteers who
had been infected with the 8FIIa strain and were shown to be positive by
seroconversion and by an IgM ELISA for NV (1). Sixteen paired sera from an
outbreak of gastroenteritis in Erie County, New York, and originally diagnosed
as NV positive by human reagent-based antigen and antibody assays were tested
(10). By genotyping (1), the outbreak from which the sera used here were
obtained was shown to be associated with a genogroup I NLV (V Ward 1/90).
Sera from patients infected with genogroup II NLVs included paired sera
obtained in two HV-inoculated volunteer studies with two volunteers each (un-
published data), along with three convalescent-phase sera from SMV-inoculated
volunteers (obtained from R. Dolin, University of Rochester). Both groups
consisted of individuals who became ill. Sera from outbreaks included 21 paired
sera from an outbreak of SMV in a New York City high school cafeteria in 1985
(16). This outbreak involved approximately 600 students and cafeteria workers.
Acute-phase sera were collected 4 to 8 days after the onset of symptoms, and
convalescent-phase sera were collected 2 weeks later. Two paired sera from
individuals infected with Taunton virus (TNV) (2) were obtained from D. Lewis,
Leeds, United Kingdom. Sera collected during investigations of two additional
outbreaks were also tested. Five paired sera and eight single convalescent-phase
sera were obtained from patients involved in an outbreak at a nursing home
(University of Massachusetts Medical Center—University Commons [UMMC-
UC]) in 1996 (unpublished data). During a 2-week period, 68 residents and staff
members became ill with gastroenteritis. Routine examination for bacterial and
parasitic agents by the University of Massachusetts Medical Center clinical
microbiology laboratory yielded negative results. Stool samples from three pa-
tients were tested by reverse transcription-PCR for NLVs. The portion se-
quenced (57 bases) had 95% identity in the polymerase region with MD-V6, a
genogroup II NLV involved in an outbreak in a Maryland nursing home in 1987
(28) (accession no. MCU07613), and 98% identity with Halifax NLV (unpub-
lished data) (accession no. NLU87651). The second outbreak involved patients
who developed gastroenteritis after a Rhode Island graduation banquet in 1986
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(unpublished data). Forty-one of 93 persons at the banquet became ill. No NV
was detected by an ELISA for NV antigen (20) in 12 stool samples from persons
involved in the outbreak. Acute-phase sera were collected 6 days after the
banquet, and convalescent-phase sera were collected 7 weeks later. Thirteen
paired sera were available; 3 of 13 seroconverted to NV in a blocking radioim-
munoassay for NV. These outbreaks were tested with both MXV and NV IgG
and IgM assays to determine the utility of these tests in outbreaks that were not
characterized with regard to viral etiology.
Paired sera were obtained from four adults involved in a documented MXV
outbreak. The outbreak was confirmed as MXV by reverse transcription-PCR
and sequencing of virus in stool samples (unpublished data). These sera also
served as positive controls for the rMXV-based IgM test.
Six paired sera were obtained from adults with astrovirus gastroenteritis (19),
and four paired sera were obtained from adults with rotavirus gastroenteritis (8).
These were tested with both MXV and NV IgG and IgM assays as controls for
the specificity of the assays for sera from persons with viral gastroenteritis due to
viruses other than NLVs.
Eighty normal human sera were obtained from a group of adult donors from
the University of Massachusetts Medical Center hospital blood bank and from
children admitted to the hospital for reasons other than gastroenteritis. All of the
above sera were stored at #220°C.
Monoclonal antibody to rMXV. A mouse monoclonal antibody to rMXV was
developed by procedures previously described (18, 27). Briefly, two inoculations
of rMXV in Titer-Max adjuvant (CytRx Corporation, Norcross, Ga.) were given
subcutaneously to BALB/c mice. After sufficient titers were obtained (1:32,000 in
an ELISA against rMXV), the spleen cells were fused to SP2/0-Ag14 mouse
myeloma cells. An ELISA was used to screen for hybridoma cells producing
anti-rMXV antibodies. The antibodies were confirmed as anti-rMXV antibodies
by a blocking antibody test with human convalescent-phase serum from a patient
who had an MXV infection. The hybridoma selected was designated clone 1B5
and was isotype IgG2a.
IgM capture antibody ELISA. Polyvinyl microtiter plates (Dynatech Labora-
tories, Inc., Chantilly, Va.) were coated with unlabeled rabbit anti-human IgM
(Fc5m) (Accurate Chemical, Westbury, N.Y.) at 0.25 mg/50 ml of 0.1 M phos-
phate-buffered saline (PBS) per well. The plates were incubated at 37°C for 2 h,
washed three times (with PBS plus 0.15% Tween 20), and blocked overnight at
20 to 22°C with 5.0% bovine serum albumin and 0.25% Bloom 60 gelatin (Sigma
Chemical Co., St. Louis, Mo.) in PBS. The plates were washed three times, and
duplicate twofold serial dilutions of human serum starting at a 1:25 dilution were
made with 50% fetal bovine serum (FBS)–50% 0.025 M Tris-HCl buffer (pH 7.2)
(FBS–Tris-HCl buffer) containing 0.015% Tween 20 (50 ml per well) and incu-
bated for 1 h at 37°C. The plates were washed five times, and 50 ng of rMXV in
50 ml of FBS–Tris-HCl buffer was added to each well of one of the duplicate
rows. To the second row, 50 ml of FBS–Tris-HCl buffer without rMXV was
added. After overnight incubation at 20 to 22°C, the plates were washed five
times, and 50 ml of a 1:5,000 dilution of monoclonal antibody to rMXV in
FBS–Tris-HCl buffer was added per well and incubated for 1 h at 37°C. The
plates were washed, and peroxidase-labeled goat anti-mouse IgG (heavy and
light chains) (Kirkegaard & Perry Laboratories, Inc., Gaithersburg, Md.) at 1
mg/ml in FBS–Tris-HCl buffer plus 1% normal rabbit serum was added and
incubated for 1 h at 37°C. The plates were washed five times. The substrate for
peroxidase (0.05 ml of O-phenylenediamine–H2O2; Abbott Laboratories, North
Chicago, Ill.) was added and allowed to stand for up to 10 min, and the reaction
was stopped with 0.1 ml of 1 N H2SO4. The A492 of the solution was measured
with a plate reader spectrophotometer (Whittaker Bioproducts, Walkersville,
Md.). A positive test was one in which a 1:25 dilution (the lowest tested) or
higher gave an A492 of $0.200 above the A492 of the control (wells with no
antigen added) and was $3 times the standard deviation of the mean A492
obtained with 10 prechallenge sera tested at a 1:25 dilution in wells with no
antigen added. Detection of IgM to rNV was done as described previously (1).
IgG antibody ELISA. Alternate rows in polyvinyl microtiter plates were coated
with rMXV at 50 ng/50 ml of 0.1 M PBS per well. The plates were incubated at
37°C for 4 h and washed three times, and all wells were blocked overnight as in
the IgM capture antibody test. The plates were washed three times, and twofold
serial dilutions of human serum starting at a 1:800 dilution were made with
FBS–Tris-HCl buffer (50 ml per well) and incubated for 1 h at 37°C. Sera with
titers of ,1:800 were retested starting at a 1:100 dilution. Dilutions for each
serum were made in both the rMXV-coated row and the control row. The plates
were washed four times, and peroxidase-labeled goat anti-human IgG (heavy and
light chains) (Kirkegaard & Perry Laboratories) at 1 mg/ml in FBS–Tris-HCl
buffer was added and incubated for 1 h at 37°C. The substrate for peroxidase was
added as described for the IgM capture antibody test, and the A492 of the
solution was measured with a plate reader spectrophotometer. A positive test
was one in which a 1:100 dilution (the lowest tested) or higher gave an A492 of
$0.200 above the A492 of the control (wells with no antigen added) and was $3
times the standard deviation of the mean A492 obtained with 10 prechallenge sera
tested at a 1:100 dilution in wells with no antigen added. Detection of IgG to rNV
was done as described previously (1).
RESULTS
The results of the serological tests for MXV from volunteer
studies and outbreaks are shown in Table 1. Among sera from
those infected with genogroup I NLVs (combined volunteer
and outbreak studies), only 3 of 25 were rMXV IgM positive;
in contrast, 24 of 25 were IgM positive for rNV. In sera from
those infected with genogroup II NLVs (combined volunteer
and outbreak studies), 28 of 47 were rMXV IgM positive and
none were IgM positive for rNV. These results show the spec-
ificity of the rMXV IgM test and confirm the specificity of the
rNV IgM test previously reported (1). In an outbreak of gas-
troenteritis not characterized with regard to viral etiology but
suspected to be due to NV (the Rhode Island graduation
banquet), 7 of 13 persons had IgM responses to rMXV,
whereas none had IgM responses to rNV. These results estab-
lished the diagnosis as genogroup II NLV. All four sera from
patients in a documented MXV outbreak were positive in the
rMXV IgM test and negative in the rNV IgM test.
Among four paired sera from children with astrovirus infec-
tions and among six paired sera from adults with rotavirus
infections, none showed seroconversion or were IgM positive
for either rMXV or rNV (Table 1). Eighty sera from nonin-
fected individuals ranging in age from 1 to 59 years were tested
for IgG and IgM to rMXV (Table 2). The proportion of sera
positive for rMXV IgG ranged from 45 to 90% for the different
age groups. Two sera from children between 1 and 4 years of
age were IgM positive for rMXV.
DISCUSSION
Several studies have shown the development of NV-specific
IgM antibodies as a result of NV infection (1, 6, 9, 13, 29, 35),
but reports on the development of IgM antibodies to geno-
group II NLV infections are limited. Two earlier studies (3, 30)
with immune electron microscopy showed IgM reactivity to
viruses that were later shown to be genogroup II NLVs, and a
recent report with an ELISA showed IgM responses to geno-
group II NLVs involved in outbreaks (17). Sera from geno-
group I NLV infections were not tested in that study. Our
results with volunteer and outbreak sera show that the rMXV-
based IgM capture ELISA that we developed detects antibod-
ies to genogroup II viruses such as HV, SMV, TNV, and
related viruses. IgM antibodies to rMXV were not detected in
sera from NV-inoculated volunteers. Neither the rMXV IgM
test nor the rNV IgM test reacted with sera from patients with
rotavirus or astrovirus infections, further demonstrating the
specificity of these tests for NLV infections.
During NV infections, IgM to NV has been found to be
more specific for NV than IgG to NV (1, 28, 34). It is well
established that repeated stimulation by a given antigen usually
increases IgG titers but decreases specificity. This situation
should not occur with the IgM response, because IgM is not
associated with anamnestic responses to repeated antigen ex-
posure. Thus, exposure to several related NLVs could result in
IgG with a broader specificity, as was seen in the seroconver-
sion data from the Erie County outbreak involving a geno-
group I NLV (V Ward 1/90). It has been shown in a previous
study that there is a correlation between seroconversion and
NLV genotype, but it was suggested in that report that the IgM
response could be more specific (33).
The MXV IgM test was most useful when used in combina-
tion with the NV IgM test for the outbreaks at UMMC-UC,
the Rhode Island graduation banquet, and in Erie County. The
lack of fourfold or greater rises in IgG antibody titers to rMXV
from patients in the outbreak at UMMC-UC was probably due
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to the late collection of the acute-phase sera. In paired sera
from two patients at the Rhode Island graduation banquet,
there were fourfold increases in IgG antibody titers to rMXV
in both patients and to rNV in one patient. Both outbreaks
were diagnosed by use of a combination of rNV- and rMXV-
based IgM capture assays. The larger sample size of the SMV
outbreak associated with eating in a school cafeteria also dem-
onstrates the utility of the rMXV-based IgM test compared
with seroconversion. Of the 13 persons found positive by either
seroconversion or IgM, only 2 were missed by the rMXV-based
IgM test, whereas 9 were missed by seroconversion.
Among 80 normal sera tested, sera from two children be-
tween 1 and 4 years old were rMXV-specific IgM positive.
Occasional positive results may occur in the rMXV-based IgM
test because high levels of IgG antibodies to MXV have been
detected in young children (5, 7, 24, 34) and the IgM-positive
sera could represent a recent infection. We did not have suf-
ficient information available on volunteer or outbreak sera to
determine the time between exposure to NLVs and the ap-
pearance of specific IgM. In a previous study on the detection
of IgM antibodies to genogroup I NLV infections (1), rNV-
specific IgM was not detected in volunteers by 5 days but was
detected by 8 days (sera from days 6 and 7 were not obtained).
In outbreak sera, rNV-specific IgM was detected 6 to 7 days
after the estimated time of exposure (1), and it is likely that
similar times for the appearance of virus-specific IgM would be
required for other NLVs.
rNV- and rMXV-based IgM capture assays can be used to
determine whether an outbreak is due to NLVs and are useful
for genogroup classification in epidemiological studies. IgM
assays are especially useful if acute-phase sera are collected
late or if paired sera are not available.
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